Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prognostic significance of PD-L1 and PD-L2 in breast cancer

Full text
Author(s):
Baptista, Mauricio Z. [1] ; Sarian, Luis Otavio [1] ; Derchain, Sophie F. M. [1] ; Pinto, Glauce A. [2] ; Vassal, Jose [2]
Total Authors: 5
Affiliation:
[1] State Univ Campinas UNICAMP, Fac Med Sci, Womens Hosp CAISM, Dept Obstet & Gynecol, BR-13083970 Campinas, SP - Brazil
[2] State Univ Campinas UNICAMP, Fac Med Sci, Womens Hosp CAISM, Lab Investigat & Mol Pathol LAPE, BR-13083970 Campinas, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: HUMAN PATHOLOGY; v. 47, n. 1, p. 78-84, JAN 2016.
Web of Science Citations: 82
Abstract

PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognostic value is still to be defined. In this study, we investigate the correlation between PD-L1 and PD-L2 protein expressions with clinical and pathologic features and disease-free survival and overall survival. To assess PD-L1 and PD-L2 expressions, we conducted immunohistochemistry studies using a breast cancer tissue microarray encompassing a total of 192 breast cancer cases, stages I, II, and III, with detailed clinical and outcome data. PD-L1 expression was present in 56.6% (107/189), and PD-L2 expression was identified in 50.8% (97/191) of breast cancer cases. Younger age at diagnosis, lymph node positivity, negative estrogen receptor, and recurrence at distant sites were all associated with both PD-L1 and PD-L2 expressions. The presence of larger tumors was associated only with PD-L1 expression. In our study, PD-L1 expression was significantly associated with better overall survival (P = .04) in breast cancer patients. Despite its association with poor clinical and pathologic features, PD-L1 expression emerges as a positive prognostic biomarker in breast cancer. This survival result might be due to the presence of a strong antitumor immune response leading to PD-L1 expression. (C) 2015 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 12/15059-8 - Evaluation of biomarkers in the detection of malignant neoplasia in women with adnexal mass
Grantee:Sophie Françoise Mauricette Derchain
Support Opportunities: Regular Research Grants
FAPESP's process: 13/25683-3 - Genomic profile comparison between Brazilian and American women with breast cancer estrogen receptor positive/HER2 negative
Grantee:Luís Otávio Zanatta Sarian
Support Opportunities: Regular Research Grants
FAPESP's process: 08/02469-8 - Genomic instability in breast malignant tumors as related to the concentration of intracelular aluminium and to estrogen receptor status
Grantee:Luís Otávio Zanatta Sarian
Support Opportunities: Regular Research Grants